Severe Chronic Neutropenia International Registry

描述（由申请人提供）：严重慢性中性粒细胞减少症国际注册（注册）于1994年开放，旨在研究粒细胞集落刺激因子（G-CSF）治疗先天性、周期性和特发性中性粒细胞减少症患者的长期安全性和有效性。登记处最初评估了血液学参数、生长发育、妊娠后果和其他重要临床事件。通过注册，我们了解到长期使用G-CSF的先天性中性粒细胞减少症患者每年演变为白血病的风险约为2%。然后，通过生物材料库的开发、连锁分析、DNA测序和细胞研究，我们了解到，循环和大多数先天性中性粒细胞减少症都可归因于编码中性粒细胞弹性酶的基因突变。我们还了解到，G-CSF受体的突变经常发生在先天性中性粒细胞减少症到急性髓性白血病的进化过程中。我们还与其他研究小组合作，研究导致中性粒细胞减少症的候选基因。该登记处目前包括1300多名患者，信息库包含来自患者、正常亲属和正常志愿者的650多个样本。

DESCRIPTION (provided by applicant): The Severe Chronic Neutropenia International Registry (the Registry) opened in 1994 to study the long-term safety and efficacy of granulocyte-colony stimulating factor (G-CSF) treatment for patients with congenital, cyclic, and idiopathic neutropenia. The Registry initially evaluated hematological parameters, growth and development, consequence of pregnancy, and other important clinical events. Through the Registry we have learned that patients with congenital neutropenia on long-term G-CSF have a risk of evolution to leukemia of approximately two percent per year. Then, through development of a repository of biological materials, linkage analysis, DNA sequencing, and cellular studies, we have learned that both cyclic and most cases of congenital neutropenia are attributable to mutations in the gene encoding neutrophil elastase. We have also learned that mutations in the receptor for G-CSF frequently occur in the course of evolution of congenital neutropenia to acute myelogenous leukemia. We have also collaborated with other research groups studying candidate genes as causes for neutropenia. The Registry currently includes more than 1300 patients and the Repository contains more than 650 samples from patients, normal relatives, and normal volunteers. The Registry is now an international research organization based at the University of Washington. In this application, we request funding to continue the work of the Registry. The specific aims are: (1) To continue to enroll and follow patients through carefully longitudinal studies, emphasizing increasing diversity of racial, age, and ethnic backgrounds; (2) To expand a bank of biological materials, to support genetic and molecular research, and to study the evolution of patients to myelodysplasia and leukemia and; (3) To enhance our efforts to disseminate information on the causes, consequences, and treatments of diseases causing severe chronic neutropenia. All of these efforts are directed toward improving understanding in the care of patients with severe neutropenia.